New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease | Biogen – Biogen October 25, 2023
FDA advisors vote against effectiveness of Biogen’s ALS drug for rare and aggressive form of the disease – CNBC March 22, 2023